Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis

Maillard, Michel H; Bortolotti, Murielle; Vader, John-Paul; Mottet, Christian; Schöpfer, Alain; Gonvers, Jean-Jacques; Burnand, Bernard; Froehlich, Florian; Michetti, Pierre; Pittet, Valérie; Juillerat, Pascal; Tutuian, Radu; Swiss Inflammatory Bowel Diseases Cohort Study Group, The (2014). Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis. Journal of Crohn's & Colitis, 8(8), pp. 825-834. Oxford University Press 10.1016/j.crohns.2013.12.026

[img] Text
8-8-825.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (641kB) | Request a copy


Anti-TNFα agents are commonly used for ulcerative colitis (UC) therapy in the event of non-response to conventional strategies or as colon-salvaging therapy. The objectives were to assess the appropriateness of biological therapies for UC patients and to study treatment discontinuation over time, according to appropriateness of treatment, as a measure of outcome.


We selected adult ulcerative colitis patients from the Swiss IBD cohort who had been treated with anti-TNFα agents. Appropriateness of the first-line anti-TNFα treatment was assessed using detailed criteria developed during the European Panel on the Appropriateness of Therapy for UC. Treatment discontinuation as an outcome was assessed for categories of appropriateness.


Appropriateness of the first-line biological treatment was determined in 186 UC patients. For 64% of them, this treatment was considered appropriate. During follow-up, 37% of all patients discontinued biological treatment, 17% specifically because of failure. Time-to-failure of treatment was significantly different among patients on an appropriate biological treatment compared to those for whom the treatment was considered not appropriate (p=0.0007). Discontinuation rate after 2years was 26% compared to 54% between those two groups. Patients on inappropriate biological treatment were more likely to have severe disease, concomitant steroids and/or immunomodulators. They were also consistently more likely to suffer a failure of efficacy and to stop therapy during follow-up.


Appropriateness of first-line anti-TNFα therapy results in a greater likelihood of continuing with the therapy. In situations where biological treatment is uncertain or inappropriate, physicians should consider other options instead of prescribing anti-TNFα agents.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine > Paediatric Gastroenterology
04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Schöpfer, Alain, Juillerat, Pascal, Tutuian, Radu


600 Technology > 610 Medicine & health




Oxford University Press




Anette van Dorland

Date Deposited:

20 Mar 2015 11:43

Last Modified:

05 Dec 2022 14:44

Publisher DOI:


PubMed ID:


Additional Information:

Christoph Müller (Institute of Pathology) ist Member of the Swiss Inflammatory Bowel Diseases Cohort Study Group

Uncontrolled Keywords:

Adalimumab, Appropriateness, Certolizumab pegol, Infliximab, Treatment discontinuation, Ulcerative colitis




Actions (login required)

Edit item Edit item
Provide Feedback